AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1999715
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy during chemotherapy administration
Trial: 6635761
Drug: Praziquantel 15
RxNorm normalized name: praziquantel 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 15 mg/kg
Trial: 24945286
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (808 nm laser irradiation as 4 J/point for 20 s over ipsilateral three nerve roots and 0.1 J/cm2 for 5 min in tangential scanning mode)
Trial: 22737868
Drug: Sanchi Tong
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanchi Tong Shu capsule
Trial: 22737868
Drug: Betahistine mesilate
RxNorm normalized name: Betahistine mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine mesilate tablets
Trial: 16050412
Drug: Elemental calcium
RxNorm normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental calcium (max 1000 to 1500 mg/day)
Trial: 8699054
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of RRV‐TV vaccine
Trial: 8699054
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of RRV‐TV vaccine
Trial: 8699054
Drug: One and
RxNorm normalized name: oxycodone and naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One and three doses of RRV‐TV vaccine
Trial: 7044294
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of amantadine
Trial: 7044294
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of rimantadine
Trial: 7044294
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of amantadine + 4 mg of chlorpheniramine
Trial: 30941562
Drug: Leuprolide mesylate
RxNorm normalized name: Leuprolide Mesylate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg
Trial: 29609146
Drug: Group psychotherapeutic
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group psychotherapeutic intervention based on cognitive‐behavioral therapy (CBT); 8 weekly, semi‐structured group meetings.
Trial: 27055643
Drug: Neostigmine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.03 mg/kg) and Atropine (0.01 mg/kg)
Trial: 24138922
Drug: Amphetamine challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine challenge in stimulant drug-naïve healthy control subjects
Trial: 24138922
Drug: Amphetamine challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine challenge in subjects matched to high-risk group on personal drug use
Trial: 22578529
Drug: Puerarin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin (1200 mg daily)
Trial: 17468814
Drug: Sivelestat (neutrophil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivelestat (neutrophil elastase inhibitor)
Trial: 11913291
Drug: 6.5% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5% hydrogen peroxide tooth-whitening gel strip, used for 30 minutes per day, twice daily for 2 months
Trial: 7695301
Drug: DU-6859a 25
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-6859a 25 mg
Trial: 7695301
Drug: DU-6859a 50
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-6859a 50 mg
Trial: 7695301
Drug: DU-6859a 100
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-6859a 100 mg
Trial: 7695301
Drug: DU-6859a 200
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-6859a 200 mg
Trial: 7695301
Drug: DU-6859a 100
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-6859a 100 mg three times a day for 6 days plus once a day on the 7th day
Trial: 7695301
Drug: DU-6859a 50
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-6859a 50 mg every 12 h for 13 doses
Trial: 7695301
Drug: DU-6859a (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DU-6859a (all doses)
Trial: 2468957
Drug: isradipine 5-10
RxNorm normalized name: isradipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isradipine 5-10 mg twice daily
Trial: 407914
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) feeding of amino acids and calories
Trial: 30664548
Drug: Driving pressure-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Driving pressure-guided ventilation (n = 145): tidal volume 6 ml/kg of ideal body weight, individualized PEEP to minimize driving pressure.
Trial: 30664548
Drug: Conventional protective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional protective ventilation (n = 147): tidal volume 6 ml/kg of ideal body weight, PEEP 5 cm H2O, and recruitment maneuver.
Trial: 24010572
Drug: 80/480 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80/480 mg tablet
Trial: 24010572
Drug: 60/360 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60/360 mg tablet
Trial: 24010572
Drug: Four standard
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four standard tablets
Trial: 24010572
Drug: Three standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three standard tablets
Trial: 21324142
Drug: Neoadjuvant imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant imatinib (IM) treatment
Trial: 21324142
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection followed by continuous IM treatment
Trial: 18851855
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 0.6 g per day plus 17-hydroxyprogesterone caproate (17-OHPC)
Trial: 15457023
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration block
Trial: 9355081
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with antilymphocyte antibodies
Trial: 9355081
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (cyclosporine, azathioprine, and prednisone)
Trial: 8202978
Drug: Electromyographic biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromyographic biofeedback treatment together with physical therapy
Trial: 27889390
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg GSE
Trial: 27889390
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg GSE
Trial: 27889390
Drug: 2500 mg
RxNorm normalized name: inulin 2500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2500 mg GSE
Trial: 25214069
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) 5 mg annually for up to three injections (years 4, 5, and 6)
Trial: 23739813
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (0.00375 mmol/kg)
Trial: 23739813
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose (0.0075 mmol/kg)
Trial: 23739813
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (0.0150 mmol/kg)
Trial: 18813412
Drug: Ginger capsules
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger capsules 3 g/day in 3 divided doses for 45 days
Trial: 18813412
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose capsule 3 g/day in 3 divided doses for 45 days)
Trial: 17059329
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MMG and CEA markers
Trial: 15312092
Drug: Machined surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Machined surface implants
Trial: 15312092
Drug: Rough-surface Tioblast
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough-surface Tioblast implants
Trial: 9313757
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous insulin infusion (1.2 +/- 0.4 U.kg‐1.day‐1)
Trial: 9313757
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (0.4 +/- 0.1 U.kg‐1.day‐1)
Trial: 9313757
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous insulin infusion
Trial: 9313757
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous insulin infusion and Intensive insulin therapy
Trial: 3780088
Drug: Intraarticular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular methylprednisolone (40 mg)
Trial: 30048006
Drug: 2 repeated
RxNorm normalized name: EICOSYL POVIDONE (2 EICOSYL BRANCHES/REPEAT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 repeated intrathecal injections of autologous bone marrow–derived mesenchymal stem cells (BM‐MSCs)
Trial: 27797708
Drug: Hesperidin 2S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hesperidin 2S (450 mg/d)
Trial: 24325594
Drug: Constraint‐induced movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced movement therapy (CIMT) program
Trial: 24325594
Drug: Conventional non‐structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non‐structured therapy program (control group)
Trial: 22890117
Drug: S(+)‐ketamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine (20 mg/70 kg for the first hour, 40 mg/70 kg for the second hour)
Trial: 16212446
Drug: clinic-directed group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinic-directed group, replicating the parameters of the early intensive behavioral treatment developed at UCLA
Trial: 1446477
Drug: Increased inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased inhaled corticosteroid (mean 1478 micrograms daily)
Trial: 1446477
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled bronchodilator (on-demand beta-agonist)
Trial: 31601479
Drug: Immediate exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate exercise (IE, during taxane chemotherapy)
Trial: 31601479
Drug: Delayed exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed exercise (DE, after chemotherapy)
Trial: 18568885
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac
Trial: 12087928
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination capsule of chloroquine (100 mg) and proguanil (200 mg)
Trial: 12087928
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of chloroquine (100 mg) and proguanil (200 mg)
Trial: 12087928
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination capsule of chloroquine and proguanil
Trial: 12087928
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of chloroquine and proguanil
Trial: 10480474
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of nisoldipine ER (20 mg)
Trial: 10480474
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of nisoldipine ER (20 mg)
Trial: 30822800
Drug: Multimodal pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal pain management protocol (preoperative intravenous acetaminophen, preincision subcutaneous bupivacaine, intraoperative intramuscular ketorolac)
Trial: 28325826
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E (800 or 1200 mg of EGCG)
Trial: 27275271
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with 970 nm diode laser irradiation
Trial: 27275271
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (0.1% triamcinolone acetonide orabase)
Trial: 16430195
Drug: Peramivir 400
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Peramivir 400 mg q24h
Trial: 16430195
Drug: Peramivir 200
RxNorm normalized name: peramivir 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peramivir 200 mg q12h
Trial: 16430195
Drug: Peramivir 400
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Peramivir 400 mg once daily
Trial: 16430195
Drug: Peramivir 800/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peramivir 800/400 mg once daily
Trial: 16430195
Drug: Peramivir 50
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Peramivir 50 mg
Trial: 16430195
Drug: Peramivir 200
RxNorm normalized name: peramivir 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peramivir 200 mg
Trial: 16430195
Drug: Peramivir 400
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Peramivir 400 mg
Trial: 16430195
Drug: Peramivir 800
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Peramivir 800 mg
Trial: 6364892
Drug: cyclandelate 400
RxNorm normalized name: cyclandelate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclandelate 400 mg qid
Trial: 31464391
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (ONS) with dietary guidance
Trial: 30015629
Drug: L-rhamnose (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-rhamnose (25 g d-1)
Trial: 30015629
Drug: L-rhamnose
RxNorm normalized name: L-rhamnose isomerase
DrugBank: Rhamnose (DB02961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-rhamnose
Trial: 24610876
Drug: Seropositive for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seropositive for HPV-16 antibodies
Trial: 24610876
Drug: Seropositive for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seropositive for HPV-18 antibodies
Trial: 22932751
Drug: PTH 1‐34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH 1‐34 (30 μg/kg daily intraperitoneal injections for 14 days)
Trial: 21221502
Drug: Food supplements
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplements
Trial: 21221502
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no food supplements)
Trial: 10470203
Drug: Monoclonal antibody-based
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody-based assay for TPA (TPA-M)
Trial: 8735197
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of immunological assays with different antibodies
Trial: 1662882
Drug: Temafloxacin 200
RxNorm normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 200 or 400 mg once daily for 3 or 7 days
Trial: 1662882
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (trimethoprim/sulfamethoxazole 160 mg/800 mg, ciprofloxacin 250 mg, or norfloxacin 400 mg, each given twice daily for 7-10 days)
Trial: 7082776
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral tablet
Trial: 7082776
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intramuscular injection
Trial: 7082776
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intramuscular injection
Trial: 7082776
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous injection
Trial: 31931172
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) treatment
Trial: 31931172
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (OAC plus antiplatelet)
Trial: 25231632
Drug: Haplotype G-5G-T
RxNorm normalized name: (T,G)-A-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplotype G-5G-T
Trial: 25231632
Drug: Haplotype A-4G-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplotype A-4G-G
Trial: 22314555
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (AHG absent)
Trial: 18654768
Drug: Escitalopram 5
RxNorm normalized name: escitalopram 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 5 mg b.i.d after 1 week
Trial: 18654768
Drug: Single-dose omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose omeprazole 40 mg
Trial: 12867221
Drug: IV gatifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV gatifloxacin 400 mg QD with option for oral stepdown gatifloxacin
Trial: 12867221
Drug: IV ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ceftriaxone 1 or 2 g QD (with or without erythromycin or clarithromycin) with option for oral stepdown clarithromycin
Trial: 29887243
Drug: Chemoradiotherapy (CRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (CRT) with daily low-dose carboplatin
Trial: 28391237
Drug: Low vitamin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low vitamin D levels (< 50 nmol/L)
Trial: 28391237
Drug: Normal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal vitamin D levels (≥ 50 nmol/L)
Trial: 23204255
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (early PN)
Trial: 23204255
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (late PN)
Trial: 23204255
Drug: Lowest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest dose of macronutrients
Trial: 23204255
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of macronutrients (administered parenterally or enterally)
Trial: 23204255
Drug: Early combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combined parenteral/enteral nutrition
Trial: 21169833
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with stem cell rescue
Trial: 21169833
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy without stem cell rescue
Trial: 18047500
Drug: Rizatriptan 10
RxNorm normalized name: rizatriptan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan 10 mg ODT
Trial: 9315420
Drug: Femcap with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femcap with nonspermicidal lubricant (K'Y gel)
Trial: 3946803
Drug: Thiopental (39.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (39.5 mg/kg)
Trial: 31229533
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (coiling)